Eton Pharmaceuticals recorded an outstanding second quarter in 2026, marked by unprecedented revenue figures and substantial margin improvements. The company's impressive growth was primarily fueled by the successful reintroduction of HEMANGEOL and consistent positive trends within its range of rare disease treatments. Strategically, Eton also expanded its pipeline through key acquisitions, notably ASN-001, which is poised to become a significant revenue driver, and IMPAVIDO, enhancing its commercial offerings. This period of rapid expansion and operational efficiency underscores Eton's commitment to leadership in the rare disease sector, demonstrating a strong financial model and a clear path toward sustained long-term value creation.
During the second quarter of 2026, Eton Pharmaceuticals announced record financial results. Total revenue soared to $37.6 million, representing a remarkable 99% increase compared to the same period in 2025. This surge was largely attributed to the successful re-launch of HEMANGEOL, an oral treatment for severe infantile hemangiomas, and strong contributions from other products in its pediatric endocrinology and rare disease portfolios. The company also achieved significant profitability, with adjusted EBITDA reaching $16.2 million, or 43% of revenue, a substantial improvement from 16% in the prior year quarter. This financial performance led Eton to raise its full-year 2026 revenue guidance to over $145 million, up from the previous $120 million, and adjusted EBITDA margin guidance to over 35%.
A pivotal moment for Eton in Q2 2026 was the re-launch of HEMANGEOL on May 1st. This initiative involved streamlining patient access through the Eton Cares program, which significantly reduced out-of-pocket costs and accelerated medication access for patients. The transition of approximately 95% of existing HEMANGEOL patients to this new distribution model by the end of June, ahead of schedule, highlighted the operational effectiveness of Eton's team. This successful re-launch positioned HEMANGEOL as Eton's leading product, driving considerable revenue growth and establishing the company's strong presence in the infantile hemangioma market. The company aims to further expand its reach, ensuring more infants receive appropriate, FDA-approved therapy instead of off-label alternatives.
Further solidifying its market position, Eton made strategic moves by licensing ASN-001 and acquiring U.S. rights to IMPAVIDO. ASN-001, a late-stage topical treatment candidate for moderate infantile hemangiomas, is expected to significantly broaden Eton's addressable market in pediatric dermatology, potentially becoming the largest revenue generator. With a simpler regulatory pathway involving a bioavailability bridging study, Eton anticipates submitting the New Drug Application in late 2027 for a potential 2028 launch. The acquisition of IMPAVIDO, an FDA-approved oral therapy for leishmaniasis, also diversifies Eton's commercial portfolio, leveraging its existing Eton Cares support system to enhance patient access and market penetration in a concentrated therapeutic area.
Eton's strategic investments extend beyond new acquisitions to enhancing its existing product lines. The pediatric endocrinology portfolio, including ALKINDI SPRINKLE and KHINDIVI, continues to show steady growth, with active patients surpassing 600. The company is actively pursuing label expansion for KHINDIVI to include younger patients, expecting approval in early 2027. DESMODA, an oral liquid desmopressin solution, launched in Q1, has garnered positive feedback from the endocrinology community for its precise dosing capabilities. In the Wilson disease franchise, Galzin continues to demonstrate strong growth through patient conversion from over-the-counter alternatives, while the pipeline candidate ET-700, an extended-release zinc acetate formulation, shows promising peak sales potential of over $100 million annually, with pilot study results expected soon. These collective efforts reflect Eton's comprehensive strategy for sustained growth and innovation in rare disease therapies.
Eton Pharmaceuticals' exceptional financial results in the second quarter of 2026 underscore its robust growth trajectory and strategic prowess in the rare disease market. The remarkable increase in revenue and adjusted EBITDA, driven by the successful HEMANGEOL re-launch and expansion into new therapeutic areas through acquisitions like ASN-001 and IMPAVIDO, highlights the company's effective business model. With ambitious long-term goals and a disciplined approach to capital allocation, Eton is well-positioned for continued success, focusing on bringing vital therapies to patients while enhancing shareholder value.
